Infinity Pharmaceuticals Inc (INFIQ)
0.00
USD |
OTCM |
Jun 25, 16:00
Infinity Pharmaceuticals Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 24, 2024 | -17.75M |
June 21, 2024 | -17.75M |
June 20, 2024 | -17.75M |
June 18, 2024 | -17.75M |
June 17, 2024 | -17.75M |
June 14, 2024 | -17.75M |
June 13, 2024 | -17.75M |
June 12, 2024 | -17.75M |
June 11, 2024 | -17.75M |
June 10, 2024 | -17.75M |
June 07, 2024 | -17.75M |
June 06, 2024 | -17.75M |
June 05, 2024 | -17.75M |
June 04, 2024 | -17.75M |
June 03, 2024 | -17.75M |
May 31, 2024 | -17.75M |
May 30, 2024 | -17.75M |
May 29, 2024 | -17.75M |
May 28, 2024 | -17.75M |
May 24, 2024 | -17.75M |
May 23, 2024 | -17.75M |
May 22, 2024 | -17.75M |
May 21, 2024 | -17.75M |
May 20, 2024 | -17.75M |
May 17, 2024 | -17.75M |
Date | Value |
---|---|
May 16, 2024 | -17.75M |
May 15, 2024 | -17.75M |
May 14, 2024 | -17.75M |
May 13, 2024 | -17.75M |
May 10, 2024 | -17.75M |
May 09, 2024 | -17.75M |
May 08, 2024 | -17.75M |
May 07, 2024 | -17.75M |
May 06, 2024 | -17.75M |
May 03, 2024 | -17.75M |
May 02, 2024 | -17.75M |
May 01, 2024 | -17.75M |
April 30, 2024 | -17.75M |
April 29, 2024 | -17.75M |
April 26, 2024 | -17.75M |
April 25, 2024 | -17.75M |
April 24, 2024 | -17.75M |
April 23, 2024 | -17.75M |
April 22, 2024 | -17.75M |
April 19, 2024 | -17.75M |
April 18, 2024 | -17.75M |
April 17, 2024 | -17.75M |
April 16, 2024 | -17.75M |
April 15, 2024 | -17.75M |
April 12, 2024 | -17.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-23.60M
Minimum
May 11 2022
332.21M
Maximum
Feb 08 2021
47.63M
Average
19.13M
Median
Feb 17 2022
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 2.982M |
Palatin Technologies Inc | 19.35M |
iBio Inc | 26.41M |
Theriva Biologics Inc | -11.08M |
Oragenics Inc | 5.495M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -9.956M |
Revenue (Quarterly) | 0.583M |
Total Expenses (Quarterly) | 10.70M |
EPS Diluted (Quarterly) | -0.11 |
Gross Profit Margin (Quarterly) | 39.62% |
Profit Margin (Quarterly) | -1.71K% |